SMTL ID : 7oau.1 (1 other biounit)

Nanobody C5 bound to Kent variant RBD (N501Y)

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.65 Å

Oligo State

hetero-1-1-mer

Ligands

1 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.1: 4 residues within 4Å: Chain A: G.10, F.13, N.14, L.39 3 PLIP interactions: 3 interactions with chain A Hydrophobic interactions: A:F.13, A:L.39 Water bridges: A:N.14

1 x GOL: GLYCEROL(Non-functional Binders)

GOL.2: 14 residues within 4Å: Chain B: A.35, I.36, G.37, F.39, R.49, C.52, A.99, L.100, G.101, A.105, C.106, D.108, N.109, P.110 3 PLIP interactions: 3 interactions with chain B Hydrogen bonds: B:G.37, B:A.99, B:D.108

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Huo, J. et al., A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nat Commun (2021)

Release Date

2021-08-11

Peptides

Spike protein S1: A
C5: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
AAA

B
BBB

Spike protein S1

C5

Related Entries With Identical Sequence